AstraZeneca, Schering to collaborate on anti-inflammatories

AstraZeneca and Schering have inked an agreement to collaborate on development and licensing of Selective Glucocorticoid Receptor Agonists (SEGRAs), potentially a new class of anti-inflammatory drugs. The two companies will jointly research and develop several SEGRAs that Schering has identified, through the end of Phase I clinical trials. After that, AstraZeneca will have an exclusive worldwide license to develop and market compounds for rheumatoid and respiratory diseases, while Schering will have the rights to all other uses of the drugs.

- read this press release for more

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.